GalNAc-Conjugated ApoCIII Antisense Oligomers for Liver Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antisense compounds targeting ApoCIII lack potency and efficacy, and there is a need for more effective treatment options for conditions associated with elevated ApoCIII levels, such as cardiovascular disease, metabolic syndrome, and diabetes.

Innovation Solution

Development of conjugated antisense compounds with a cleavable moiety attached to the 5' end of an oligonucleotide, utilizing a GalNAc cluster to enhance uptake into liver cells, particularly hepatocytes, and incorporating phosphodiester linkages to improve activity and tolerability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antisense compounds are used to target ApoCIII, then gene expression modulation is achieved, but potency and efficacy are insufficient

Engineering Contradiction:

Improvepotency and efficacyVSAvoidtreatment effectiveness

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies composite materials by combining the antisense oligonucleotide with a GalNAc cluster conjugate. This composite structure integrates the gene-silencing capability of the antisense compound with the enhanced liver cell uptake properties of the GalNAc cluster, thereby improving both potency and efficacy for treating conditions associated with elevated ApoCIII levels

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The GalNAc cluster acts as an intermediary that facilitates the delivery of the antisense compound into liver cells. This mediator enables the antisense oligonucleotide to reach its target more effectively, overcoming the limitation of insufficient potency and efficacy observed with conventional antisense compounds

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If conjugated antisense compounds with GalNAc cluster are used to enhance liver cell uptake, then delivery to liver tissue is improved, but kidney exposure may increase

Engineering Contradiction:

Improvedelivery to liver tissueVSAvoidkidney exposure

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing the GalNAc cluster conjugate to have specific affinity for liver cells (hepatocytes) while minimizing interaction with other tissues. This localized targeting improves delivery to the intended organ while reducing off-target effects, thereby enhancing liver tissue delivery without proportionally increasing kidney exposure

Inventive Principle:

Principle #3Local quality

3Stability of the object's composition

If chemical modifications are incorporated to enhance nuclease resistance, then compound stability is improved, but complexity of synthesis increases

Engineering Contradiction:

Improvenuclease resistanceVSAvoidsynthesis complexity

Core Design Contradiction:

Stability of the object's compositionVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of the oligonucleotide backbone and nucleosides to alter their resistance to nuclease degradation. These parameter changes in chemical composition provide enhanced stability without requiring overly complex synthetic pathways, balancing improved stability with manufacturability

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The conjugated antisense compounds demonstrate increased potency and delivery to liver tissue, reduced kidney exposure, and improved tolerability, offering enhanced therapeutic potential for conditions associated with ApoCIII.

Implementation Method 1

The principle behind antisense technology is that an antisense compound hybridizes to a target nucleic acid and modulates the amount, activity, and/or function of the target nucleic acid

Methodology Applied

Scientific EffectHybridization:

Implementation Method 2

utilizing a GalNAc cluster to enhance uptake into liver cells, particularly hepatocytes

Methodology Applied

Scientific EffectCellular uptake enhancement:

Implementation Method 3

conjugated antisense compounds with a cleavable moiety attached to the 5' end of an oligonucleotide

Methodology Applied

Scientific EffectCleavage:

Data Source

PatentUS12509684B2Compositions and methods for modulating apolipoprotein C-III expression

Publication Date: 2025.12.30 IONIS PHARMACEUTICALS INC

AI summary

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.